Crizotinib treatment for advanced non-small-cell lung cancer patients: a budget impact analysis based in Thailand

© 2017 Informa UK Limited, trading as Taylor & Francis Group. Objective: With the advent of the anaplastic lymphoma kinase (ALK) inhibitor, treatment of ALK-positive advanced non-small-cell lung cancer (NSCLC) patients has become more effective while drug costs are still a major concern. This...

Full description

Saved in:
Bibliographic Details
Main Authors: Thongprasert S., Permsuwan U.
Format: Journal
Published: 2017
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85015768144&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/40463
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University